HosTIL territory: mapping the landscape of toxicity in TIL therapy - PubMed
3 hours ago
- #Toxicity
- #TIL Therapy
- #Adverse Events
- TIL therapy recently approved for advanced melanoma refractory to first-line immune checkpoint inhibitors.
- Toxicities primarily linked to induction chemotherapy and high-dose interleukin-2 (HD-IL-2), not the TIL product.
- Common adverse events include cytopenias, fever, gastrointestinal symptoms, kidney injury, rash, and alopecia.
- Severe but less frequent toxicities include neutropenic sepsis, cytokine release syndrome, and cardiac dysfunction.
- Toxicity typically resolves within 10-12 days post-infusion but requires intensive supportive care.
- No validated biomarkers exist to predict toxicity risk, highlighting the need for further research.
- Combining TIL therapy with other immunomodulatory agents may increase toxicity and complicate management.